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ABSTRACT
Breast cancer remains the most common malignancy
in women. Since the late 1980s, significant advances
have been made in the treatment of this cancer. Those
advances, particularly the ones in the adjuvant set-
ting, have led to declines in the mortality associated
with breast cancer. But another result has been treat-
ments that are more complex and that potentially carry
more toxicity. One key toxicity related to the adju-
vant therapy of breast cancer is cardiac toxicity. Some
of the agents commonly used for the treatment of
breast cancer, including anthracyclines, trastuzumab,
and possibly even aromatase inhibitors, have been
associated with cardiac toxicity. The present article
reviews the current understanding of cardiac toxicity
risk and strategies to minimize cardiac morbidity as-
sociated with cytotoxic chemotherapy, trastuzumab
therapy, and hormonal therapy with aromatase inhibi-
tors for early-stage breast cancer.
KEY WORDS
Anthracyclines, trastuzumab, aromatase inhibitors,
cardiac toxicity
1. INTRODUCTION
In Canada, breast cancer is the most common malig-
nancy in women. During the last 15 years, an esti-
mated 162,600 Canadian women were diagnosed with
breast cancer, with more than 22,000 new cases di-
agnosed annually 1. Following surgery, nearly all af-
fected women will receive some form of adjuvant
systemic therapy—cytotoxic chemotherapy, endo-
crine therapy, targeted therapy with a monoclonal
antibody, or a combination—to reduce their risk of
relapse and to improve survival. As a result of this
improved adjuvant therapy and earlier detection with
mammographic screening, the age-adjusted mortal-
ity of early-stage breast cancer continues to decline,
with 96% and 86% of stage I and II patients respec-
tively expected to survive more than 5 years from
initial diagnosis 1.
Given a burgeoning population of long-term breast
cancer survivors and an increasing recognition that
breast cancer is a molecularly heterogeneous disease
in which only subgroups of patients may benefit from
specific adjuvant therapies 2–6, minimizing the long-
term side effects of treatment is now of utmost sig-
nificance. Cardiac toxicity, which is among the most
dreaded of the long-term complications of cancer treat-
ment, has been reported with all three forms of adju-
vant systemic therapy for breast cancer. The present
article reviews the current understanding of cardiac
toxicity risk and strategies to minimize cardiac mor-
bidity associated with cytotoxic chemotherapy, tras-
tuzumab therapy, and hormonal therapy with
aromatase inhibitors (AIs) for early-stage breast cancer.
2. ANTHRACYCLINE-INDUCED
CARDIOTOXICITY
The anthracycline class of chemotherapeutic agents
is commonly used to treat a variety of malignancies,
including breast, gastric, and esophageal cancers, and
sarcoma, lymphoma, and leukemia. A large meta-
analysis of early clinical trials in breast cancer es-
tablished the superiority of anthracycline-based
adjuvant chemotherapy over the traditional cyclo-
phosphamide, methotrexate, and 5-fluorouracil (CMF)
regimen with an absolute 4% improvement in over-
all survival at 10 years 7. Following the introduction
of anthracyclines, more recent clinical trials have
tried to define the optimal type, dose, and schedule
of anthracycline administration; the value of adding
agents such as taxanes and targeted therapies to an
anthracycline backbone; and the possible alternatives
to anthracycline-based therapy 8,9.
Starting with their initial use in the 1960s, anthra-
cyclines were recognized to potentially cause a vari-
ety of cardiac side effects. Rare acute toxicities
include supraventricular tachycardia, electrocardio-
graphic changes, ventricular ectopy, myopericardi-
tis, and sudden death 10. A serious long-term side
effect of anthracycline therapy is the development of
a dilated cardiomyopathy highlighted by systolic
dysfunction and left-sided congestive heart failure 11,
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which usually occurs 2–5 years after the last anthra-
cycline dose. Late anthracycline-induced cardiomy-
opathy can develop insidiously, without significant
evidence of systolic dysfunction on traditional mea-
sures of left ventricular ejection fraction (LVEF) 12 such
as multiple gated acquisition scans or two-dimen-
sional echocardiography. After the onset of symp-
toms of congestive heart failure (CHF) secondary to
anthracycline-induced cardiomyopathy, outcome is
quite poor, with a median survival of approximately
1 year in a large population-based series 13.
2.1 Pathogenesis
The pathophysiology of anthracycline-induced car-
diomyopathy is poorly understood. Myocardial cells
demonstrate a limited capacity to regenerate, and they
are particularly susceptible to the degenerative ef-
fects of cytotoxic chemotherapy. Endomyocardial
biopsies from patients with anthracycline-induced
cardiomyopathy demonstrate irreversible myofibril
loss, necrosis, and vacuolar degeneration 14. Although
numerous mechanisms have been proposed to ac-
count for these morphologic features, most studies
suggest that anthracyclines cause myocardial dam-
age through oxidative stress 15. Anthracyclines form
complexes with intracellular iron, leading to the gen-
eration of free radical species, lipid peroxidation, and
depletion of antioxidants. These events leave myo-
cardial cells susceptible to oxidative injury affecting
nucleic acids, intracellular proteins, and mitochon-
dria, which accumulate damage and ultimately trig-
ger cell death.
2.2 Risk Factors for Anthracycline-Induced
Cardiomyopathy
A number of risk factors are associated with the de-
velopment of anthracycline-induced cardiomyopathy.
A landmark retrospective review by Von Hoff et al. 16
established a clear relationship between the cumula-
tive dose of doxorubicin and the risk of CHF. In their
series, the incidence of CHF after 400 mg/m2 of doxo-
rubicin was 3%, rising to 7% at 550 mg/m2 and 18%
at 700 mg/m2. Other traditional risk factors associ-
ated with anthracycline-induced cardiomyopathy in-
clude age greater than 70 years 16,17, mediastinal
radiation (concurrent or sequential) 17–21, pre-exist-
ing cardiac disease 17,20, hypertension 17,19, and liver
disease 22. For reasons that are poorly understood,
women are more susceptible to anthracycline-induced
cardiomyopathy: as compared with men, they have a
lower cumulative-dose threshold 23.
2.3 Incidence of Anthracycline-Induced
Cardiomyopathy
Because most multi-agent adjuvant breast cancer
chemotherapy regimens deliver a cumulative dose of
doxorubicin below 450 mg/m2, the risk of cardiac
toxicity with anthracycline-based therapy was initially
felt to be low. The early adjuvant trials of
anthracyclines in breast cancer supported this notion
of cardiac safety. In a meta-analysis by the Early
Breast Cancer Trialists’ Collaborative Group, the
mortality from heart disease was 0.08% annually in
the anthracycline-treated group as compared with
0.06% annually in the non-anthracycline CMF group 7.
A retrospective analysis from a single centre reported
a 1% incidence of CHF at a median follow-up of
14 years in a group treated with doxorubicin–CMF;
no CHF events were reported in the CMF-only group 24.
However, these early reports included only relatively
young patients with few medical comorbidities; they
suffered from incomplete reporting and lacked pro-
spective serial cardiac assessment.
More recent population-based studies suggest that
the cardiac sequelae from anthracycline-based treat-
ment may be much higher than previously thought.
In a review of 31,748 women over the age of 65 years
diagnosed with early-stage breast cancer in the Sur-
veillance Epidemiology and End Results (SEER)–
Medicare database from 1992 to 1999, women who
received doxorubicin-based adjuvant chemotherapy
were 2.5 times more likely to be diagnosed with car-
diomyopathy than were women who did not receive
chemotherapy 25. This increased risk of cardiomyopa-
thy in the doxorubicin-treated group was observed
despite a lower prevalence of pre-existing heart dis-
ease in the doxorubicin group before initiation of
therapy. Similarly, a separate analysis of the SEER da-
tabase reported a 38.4% rate of CHF at 10 years in
anthracycline-treated women aged 66–70 years as
compared with rates of 32.5% and 28% in women of
the same age group who received non-anthracycline
chemotherapy and no adjuvant chemotherapy respec-
tively 26,27.
Beyond clinically overt CHF, anthracycline-based
adjuvant therapy is also associated with subclinical
cardiomyopathy. Longer follow-up of early adju-
vant anthracycline-based clinical trials has demon-
strated that administration of “safe” cumulative
doses of doxorubicin below 450 mg/m2 may pre-
dispose to asymptomatic systolic dysfunction, re-
garded as a reduction of 10% or more from baseline
in LVEF. In the National Cancer Institute of Canada
MA.5 trial, which randomized women with node-posi-
tive breast to 6 cycles of a cyclophosphamide,
epirubicin, and 5-fluorouracil (CEF) regimen or to
6 cycles of CMF, 25% of women who received CEF
developed an asymptomatic decline of 10% or more
in LVEF after 5 years; in the CMF group, just 9% de-
veloped an equivalent decline 28. Similarly, the North
Central Cancer Treatment Group (NCCTG) N9831 In-
tergroup Adjuvant Trial, which used doxorubicin and
cyclophosphamide (AC) followed by paclitaxel (T)
as a backbone for the addition of trastuzumab therapy
in women with human epidermal growth factorCARDIAC TOXICITY
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receptor type-2 (HER2) overexpression, reported that
23.4% of patients experienced a 10% or greater de-
cline in LVEF following 4 cycles of AC 29. The long-
term clinical impact of this form of subclinical
cardiomyopathy is unclear. However, an asymptom-
atic decline in LVEF may limit the use of further sys-
temic therapies that are potentially cardiotoxic. For
example, in the N9831 trial, 7.5% of women would
not have been eligible to receive trastuzumab with
paclitaxel following 4 cycles of AC because of a de-
cline in LVEF from baseline 30.
2.4 Strategies to Reduce Anthracycline-Induced
Cardiomyopathy
The success of trastuzumab has rekindled enthusiasm
for developing strategies to minimize anthracycline-
induced cardiac dysfunction (Table I). Substituting
epirubicin for doxorubicin reduces the incidence of
clinical heart failure in the metastatic setting 31. Pro-
longed infusion time and weekly administration of
doxorubicin also cause less cardiotoxicity than the
standard every-three-weeks bolus administration that
is routinely used in clinical practice 32, but the fre-
quency of hospital visits for weekly administration
and the shortage of resources for prolonged infusions
make these options unappealing for patients and pro-
viders alike. Liposomal formulations of anthracyclines
and the use of adjunctive scavengers of free radicals
such as dexrazoxane have also been shown to reduce
the incidence of CHF in the treatment of metastatic dis-
ease 33–35. However, no prospective clinical trials are
currently evaluating these agents in the adjuvant set-
ting. Beta-blockers 36 and angiotensin converting-
enzyme inhibitors 37 used in combination with
anthracyclines have also demonstrated promise; how-
ever, the single-centre studies of these combinations
have involved small numbers of patients receiving a
variety of chemotherapy combinations with limited
long-term follow-up.
To be able to determine which patients should be
targeted with cardioprotective strategies in future
clinical trials, predictive markers of anthracycline-
induced cardiac injury are needed. In a pooled analy-
sis of three trials with serial monitoring of left
ventricular function, more than one third of patients
who went on to develop CHF secondary to doxorubi-
cin did not demonstrate a greater than 30% reduction
in LVEF before the onset of symptoms 12. Monitoring
of LVEF is clearly an imprecise surveillance tool; it
cannot reliably predict which patients with asymp-
tomatic LVEF decline are at risk of future cardiac
events. Moreover, significant CHF can occur without
a preceding decline in LVEF.
There is hope that alternative techniques of myo-
cardial imaging may provide better discriminative
power. In many other forms of cardiomyopathy, sys-
tolic dysfunction precedes a diastolic dysfunction.
Indices of early diastolic dysfunction detectable by
angiocardiography may predict anthracycline-in-
duced cardiotoxicity more reliably than traditional
multiple gated acquisition monitoring does 38. Bio-
chemical monitoring with troponin 39–43 or B-type
natriuretic peptide 44 as early markers of anthracy-
cline-induced myocardial injury may also eventually
play a role.
Perhaps the most effective strategy for reducing
the risk of cardiotoxicity is to limit anthracycline
administration to the patients most likely to benefit
from adjuvant anthracycline therapy. A recent U.S.
Oncology Group trial demonstrated improved dis-
ease-free survival (DFS) for early-stage breast cancer
treated with docetaxel and cyclophosphamide (TC)
over standard AC 45. As a result, it may be appropri-
ate to use TC for early-stage breast cancer patients
with a lower risk of cancer recurrence and risk fac-
tors for anthracycline cardiotoxicity. For patients
with an elevated risk of breast cancer recurrence, in
whom clinicians would be inclined to use an anthra-
cycline followed by a taxane, it may be possible to
use molecular markers such as co-amplification of
topoisomerase IIa (TOP2A) and HER2 as predictors
of benefit from adjuvant anthracycline-based
therapy 46–50. However, the hypothesis that co-am-
plification of TOP2A and HER2 predicts anthracycline
sensitivity has yet to be prospectively validated in a
clinical trial.
In the future, technology base on gene expres-
sion may provide valuable insights into which mo-
lecular subsets of breast cancer benefit from adjuvant
chemotherapy and therefore warrant the risk of long-
term toxicity. However, until prospective clinical tri-
als establish effective alternatives to anthracyclines
for patients with an elevated recurrence risk, more
research is needed to define risk factors, predictive
markers, and effective preventive strategies to mini-
mize the burden of anthracycline-induced
cardiotoxicity.
3. TRASTUZUMAB
Approximately 20% of breast cancers amplify or
overexpress  HER2 51 (sometimes both). Amplification
or overexpression of HER2 is associated with an ag-
TABLE I Risk factors and strategies to prevent anthracycline-
induced cardiotoxicity
Risk factors Prevention strategies
Cumulative anthracycline dose Alternative anthracyclines
Increased age Liposomal formulations
Mediastinal radiation Weekly administration
Pre-existing cardiac disease Prolonged infusion
Hypertension Adjunctive dexrazoxane
Liver disease ? Adjunctive beta-blockers or
Female sex Angiotensin converting-enzyme
inhibitorsTOWNS et al.
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gressive breast cancer phenotype 52. Tumours with
HER2 amplification or overexpression are more likely
to demonstrate poor differentiation, high nuclear
grade, and high proliferative rates. They are also as-
sociated with an increased risk of lymph-node me-
tastasis and decreased estrogen and progesterone
receptor expression 53. These observations led to the
development of trastuzumab (Herceptin: Genentech,
San Francisco, CA, U.S.A.), a humanized monoclonal
antibody against HER2.
In 2001, a pivotal clinical trial by Slamon et al. 54,
which involved 469 patients with previously un-
treated HER2-positive metastatic breast cancer, ran-
domized patients to chemotherapy alone versus
chemotherapy with trastuzumab. As compared with
the chemotherapy-alone group, the chemotherapy-
plus-trastuzumab group experienced increased time
to disease progression (7.4 months vs. 4.6 months,
p < 0.001) and an increased response rate (50% vs.
32%; p < 0.001) 54. Similar results were seen when
trastuzumab was studied in combination with
docetaxel 55. These encouraging results prompted
study of trastuzumab in the adjuvant setting.
To date, five phase III trials have studied trastu-
zumab in early-stage breast cancer: the NCCTG Inter-
group trial N9831, the National Surgical Adjuvant
Breast and Bowel Project (NSABP) trial B-31 (which
led to a combined analysis with NCCTG N9831), the
Herceptin Adjuvant (HERA) trial, the Breast Cancer
International Research Group (BCIRG) trial 006, and
the Finland Herceptin (FinHER) trial.
3.1 Adjuvant Trastuzumab Trials for Early-Stage
Breast Cancer
The NCCTG N9831, HERA, BCIRG 006, and FinHER trials
evaluated the addition of trastuzumab to adjuvant
chemotherapy for node-positive or high-risk node-
negative  HER2-positive breast cancer; NSABP B-31 en-
rolled only node-positive patients (Table II) 56–60. The
most notable design differences across these trials
involved sequential versus concurrent use of trastu-
zumab with adjuvant chemotherapy, and the admin-
istration of anthracyclines.
The NSABP B-31 trial evaluated concurrent use of
trastuzumab with adjuvant chemotherapy. The NCCTG
N9831 trial involved two groups with regimens simi-
lar to those in the NSABP B-31 trial, but it also involved
a third group that received sequential trastuzumab
following adjuvant chemotherapy. This last group was
not included in the joint analysis of these two trials,
but its preliminary results provided insight on the
relative efficacy of trastuzumab when used concur-
rently with, or sequentially after, the administration
of adjuvant chemotherapy.
The HERA trial provided data applicable to a wide
range of chemotherapeutic regimens. In that study,
94% of participants received anthracyclines, and 26%
received both anthracyclines and taxanes before ran-
domization 56. The HERA trial will also provide data
on duration of trastuzumab and whether 2 years of
treatment with trastuzumab is more beneficial than
1 year of treatment.
The BCIRG 006 trial had a third arm (a combina-
tion of docetaxel, carboplatin, and trastuzumab) that
did not contain an anthracycline, providing informa-
tion on whether trastuzumab is effective with non-
anthracycline-based chemotherapy.
The FinHER trial randomly assigned 1010 patients
to docetaxel or vinorelbine followed by 5-fluoro-
uracil, epirubicin, and cyclophosphamide for 3 cycles.
The 232 HER2-positive patients from this study were
further randomized to trastuzumab or observation,
and trastuzumab was given concurrently over 9 weeks
with either docetaxel or vinorelbine.
The primary endpoint of all of the foregoing stud-
ies was either DFS or recurrence-free survival 56–60.
The secondary endpoints included overall survival
and time to distant recurrence 56–60. All of these trials
have now reported an approximate 50% reduction in
the risk of recurrence for patients assigned to receive
adjuvant trastuzumab (Table II) 56–60.
3.2 Trastuzumab-Induced Cardiotoxicity
Early clinical trials with trastuzumab in patients with
metastatic disease did not prospectively monitor for
cardiac toxicity 51,62. However, the independent Car-
diac Review and Evaluation Committee (CREC) retro-
spectively reviewed patients enrolled in seven phase II
and III trials to evaluate the risk of cardiac dysfunction
associated with trastuzumab 63. The AC combination
with trastuzumab had the highest rates of cardio-
toxicity with a 27% incidence of cardiac dysfunction,
including a 16% incidence of New York Heart Asso-
ciation (NYHA) class III/IV heart failure 63. In compari-
son, cardiac dysfunction developed in 13% of patients
treated with paclitaxel and trastuzumab (including 2%
NYHA class III and IV CHF) and in 3%–7% of patients
treated with trastuzumab alone 63. The CREC concluded
that, given the 25% improvement in overall survival
associated with the use of trastuzumab in metastatic
disease 55, the benefits of trastuzumab in patients with
HER2-positive breast cancer outweighed the risk of
cardiac dysfunction 63. Also, based on the high rates
of cardiac dysfunction noted in relevant populations,
anthracyclines and trastuzumab should no longer be
used concurrently in clinical practice. The observa-
tions by the CREC led to the development of strict in-
clusion and exclusion criteria and guidelines for
prospective cardiac monitoring in adjuvant trials.
3.2.1 Cardiac Eligibility Criteria and Cardiac Monitoring
Most of the adjuvant trastuzumab trials had cardiac
eligibility criteria that required a LVEF of more than
50% and that excluded patients with a history of car-
diac disease or cardiac risk factors (Table III) 56,58,59,
61,64. The HERA trial was the exception, using a LVEFCARDIAC TOXICITY
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cut-off of more than 55%. In the combined analysis
of NSABP B-31 and NCCTG N9831, patients were ex-
cluded from trastuzumab initiation if their LVEF after
anthracycline therapy was below the lower limit of
normal or had declined by more than 15% from base-
line, or if clinically significant cardiac symptoms had
developed after treatment with anthracyclines 64.
Based on those criteria, 233 of 3497 patients (6.7%)
who had completed doxorubicin and cyclophospha-
mide therapy were not able to initiate trastuzumab
therapy 64. Similarly, in the BCIRG trial, approximately
2.4% of patients did not go on to receive trastuzu-
mab after anthracycline therapy 61.
The adjuvant trials also rigorously monitored LVEF
at baseline and throughout the study period, includ-
ing after anthracycline administration. The HERA trial
has the longest prospective LVEF follow-up of the ad-
juvant trials to date, with a final LVEF assessment at
60 months after randomization 56.
3.2.2 Definition of Cardiac Toxicity and Criteria to
Discontinue Trastuzumab
Although all five adjuvant trials evaluated cardiac
dysfunction, their definitions of cardiac events and
their guidelines for discontinuation or reintroduction
of trastuzumab after documentation of a cardiac event
showed subtle differences (Table III) 56,58,59,61,64. All
five trials defined cardiac death and symptomatic
heart failure as cardiac endpoints. However, they used
variable definitions for significant LVEF declines from
baseline and absolute LVEF cut-offs (Table III) 56,58,59,
61,64. The NSABP B-31 and NCCTG N9831 trials defined
cardiac endpoints as cardiac death or symptomatic
heart failure (NYHA III/IV), confirmed by a cardiac re-
view panel 30; on the other hand, the HERA trial used
cardiac death or symptomatic heart failure (NYHA III/
IV) with a drop in LVEF of at least 10% from baseline
and below an absolute value of 50% 56. These differ-
ences across the trials make direct comparison of their
TABLE II Clinical trial design and efficacy results for trials of adjuvant trastuzumab in early-stage breast cancer
Trial Regimen Patients Median DFS HR Overall HR
(n) follow-up (%) (95% CI/ survival (95% CI/
(months) p value) (%) p value)
Combined analysis AC®paclitaxel 1989 36 73.1 0.48 89.4 0.65
(NSABP B-31, (0.41 to 0.57/ (0.51 to 0.84/
NCCTG N9831) 57 <0.00001) 0.0007)
AC®paclitaxel plus trastuzumab for 1 year 1979 85.9 92.6
NCCTG N9831 AC®paclitaxel®trastuzumab 985
HERA 56,58 Chemotherapy®observation 1698 23.5 74.3 0.64 89.7 0.66
(0.54 to 0.76/ (0.47 to 0.91/
<0.0001) 0.0115)
Chemotherapy®trastuzumab for 1 year 1703 80.6 92.4
Chemotherapy®trastuzumab for 2 years 1701
BCIRG 006 60,61 AC®docetaxel 1073 36 77 86
AC®docetaxel plus trastuzumab for 1 year 1074 83 0.61 92 0.59
(0.48 to 0.76/ (0.42 to 0.85/
<0.0001 0.004
compared with compared with
AC®docetaxel AC®docetaxel
group) group)
Docetaxel plus carboplatin plus trastuzumab 1075 82 0.67 91 0.66
for 1 year (0.54 to 0.83/ (0.47 to 0.93/
0.0003 <0.017
compared with compared with
AC®docetaxel AC®docetaxel
group) group)
FinHER 59 Docetaxel®FEC 58 35 77.6 89.7
Vinorelbine®FEC 58
Docetaxel plus trastuzumab (9 weeks) 54 37 89.3 0.42 96.3 0.41
®FEC (0.21 to 0.83/ (0.16 to 1.08/
0.01) 0.07)
Vinorelbine plus trastuzumab (9 weeks) 62
®FEC (HER2-positive
subset)
DFS = disease-free survival; HR = hazard ratio; CI = confidence interval; NSABP = National Surgical Adjuvant Breast and Bowel
Project; NCCTG = North Central Cancer Treatment Group; AC = doxorubicin, cyclophosphamide; FEC = fluorouracil, epirubicin,
cyclophosphamide.T
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TABLE III Cardiac criteria for trials of adjuvant trastuzumab in early-stage breast cancer
NSABP B-31 30,64 NCCTG N9831 64 HERA 56,58 BCIRG 006 60,61 FinHER 59
Cardiac LVEF < LLN LVEF < LLN LVEF < 55% by echocardiography Full description not yet Age > 66 years
 exclusion History of History of or MUGA after all chemotherapy published Severe hypertension
 criteria • angina pectoris requiring • angina pectoris requiring and radiotherapy Approximately, Cardiac disease, including
anti-angina medication anti-angina medication • age > 70 years • heart failure of any
• arrhythmias requiring • arrhythmias requiring History of • LVEF < 50% at baseline degree
medication medication • documented CHF • arrhythmia requiring
• severe conduction • severe conduction • CAD with previous Q-wave MI regular medication
abnormality abnormality • angina pectoris requiring • MI in the last 12 months
• clinically significant • clinically significant medication
valvular disease valvular disease • uncontrolled hypertension
• cardiomegaly on chest • cardiomegaly on chest • clinically significant valvular
radiograph radiograph disease
• poorly controlled • Poorly controlled • unstable angina
hypertension hypertension
• MI, CHF, or cardiomyopathy • MI, CHF, or cardiomyopathy
• left ventricular hypertrophy • clinically significant
on echocardiography pericardial effusion
Cardiac Assessment of LVEF with Assessment of LVEF with MUGA Responses to a cardiac Similar to NSABP B-31 Assessment of LVEF with
 monitoring  MUGA before randomization  or echocardiography before  questionnaire, physical exam, MUGA or echocardiography
 and at 3, 6, 9, 18 months  randomization and at 3, 6, 9,  12-lead ECG, and assessment of  at baseline, after the last
 after randomization  18 months after randomization  LVEF with MUGA or echocardiog-  FEC cycle, and 12 and
 raphy at baseline, and at 3, 6, 12,  36 months after
 18, 24, 30, 36, 60 months after  chemotherapy
 randomization
Cardiac Definitive or probable Definitive or probable cardiac Cardiac death Definitive or probable cardiac Cardiac death
 endpoint  cardiac death  death Severe CHF defined as NYHA  death Symptomatic CHF
 definitions Heart failure with NYHA Heart failure with NYHA  class III or IV (functional class Symptomatic CHF
 class III/IV symptoms  class III/IV symptoms  confirmed by a cardiologist) MI
Asymptomatic (NYHA class I) or  and a decrease in LVEF of at Asymptomatic decline in LVEF
 mildly symptomatic (NYHA  least 10% below baseline and  of more than 15% from baseline
 class II) with declines in LVEF of  to less than 50%  or of more than 10% from
 10% or more from baseline to a Grade 3 or 4 ischemia/infarction  baseline resulting in an LVEF of
 level of 50% or less Grade 3 or 4 arrhythmias  less than 50%
Asymptomatic LVEF decline,
 defined as an absolute LVEF
 decline of more than 15% or LVEF
 below the lower limit of normal
Criteria Asymptomatic decline in Asymptomatic decline in LVEF Asymptomatic, and LVEF of 45% Similar to NSABP B-31 Not reported
 to hold  LVEF of more than 15% or  of more than 15% or to below  or lower or LVEF of 50% or lower
 trastuzumab to below the LLN  the LLN  and declined by at least 10%
 from baseline continuedCARDIAC TOXICITY
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results difficult. The HERA, BCIRG, and FinHER trials
also included asymptomatic declines in LVEF as a car-
diac endpoint, again using different LVEF cut-offs in
their definitions. The BCIRG trial differed in that it also
included grade 3 or 4 ischemia or infarction and
grade 3 or 4 arrhythmia as cardiac endpoints 61. The
FinHER trial also reported myocardial infarction as a
cardiac endpoint 59.
In the combined analysis and in the HERA trial,
the criteria for withholding or discontinuing trastu-
zumab are similar; however, HERA uses a lower LVEF
cut-off of less than an absolute value of 45% (rather
than 50%, as in the combined analysis). In NSABP B-31,
NCCTG N9831, HERA, and BCIRG 006, an absolute dif-
ference of more than 4% in the incidence of cardiac
death or severe CHF between the trastuzumab group
and the observation group would have provoked early
discontinuation of the study 62. This circumstance did
not occur in any of the trials.
3.3 Cardiac Risk in Trastuzumab Adjuvant Trials
In the trastuzumab adjuvant trials, the use of adjuvant
trastuzumab was associated with an absolute increase
in the risk of symptomatic CHF of between 0.6% and
3.8% (Table IV) 30,57–60,66. In the combined analysis of
the NSABP B-31 and NCCTG N9831 trials, 14.2% of pa-
tients (164 of 1159) had asymptomatic reductions in
LVEF before the planned completion of 52 weeks of
trastuzumab therapy 65. In the NSABP B-31 trial, 133 of
714 patients (19%) in the trastuzumab arm had to dis-
continue trastuzumab for symptomatic (31 patients)
or asymptomatic (102 patients) declines in LVEF 30.
In the HERA trial, 72 participants (4.3%) discon-
tinued trastuzumab because of cardiac problems 58.
As compared with the NSABP B-31 and NCCTG N9831
trials, the HERA trial also reported a lower incidence
of severe CHF in the trastuzumab group (0.6% vs. 3.8%
and 3.5% respectively) 58. It has been hypothesized
that these differences can be attributed to the sequen-
tial rather than concurrent use of trastuzumab with
chemotherapy, the longer time interval between
completion of chemotherapy and initiation of trastu-
zumab administration (3 months on average in the
HERA trial), and the higher LVEF required as inclusion
criteria in the HERA trial (above 55% as compared with
above 50% in the combined analysis) 58.
The BCIRG 006 trial reported a significant differ-
ence in symptomatic cardiac events between the AC/
docetaxel group and the AC/docetaxel/trastuzumab
group 61. However, no statistically significant differ-
ence in cardiac events was observed between the AC/
docetaxel arm and the docetaxel/carboplatin/trastu-
zumab arm 61. Also, at 23 months’ follow-up, no sta-
tistically significant difference in DFS was observed
between the AC/docetaxel/trastuzumab (anthracycline-
containing) arm and the docetaxel/carboplatin/tras-
tuzumab (non-anthracycline-containing) arm (hazard
ratios of 0.49 and 0.61 respectively) 61, suggestingTOWNS et al.
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that non-anthracycline/trastuzumab–containing regi-
mens may be as effective as anthracycline/trastuzu-
mab–containing regimens, with a lower rate of cardiac
toxicity.
The only trial that reported no increased risk of
cardiac toxicity in the trastuzumab group was FinHER.
Surprisingly, an increased risk of symptomatic and
asymptomatic heart failure was observed in the non-
trastuzumab arm (statistical significance not re-
ported) 59. The major differences in this trial were the
smaller study population (n = 232) and the duration
of trastuzumab therapy (9 weeks).
3.3.1 Risk Factors for Trastuzumab-Induced
Cardiotoxicity
The risk factors for trastuzumab-induced cardio-
toxicity have not been clearly defined. The NSABP B-31
trial reported increased age (p = 0.03), baseline LVEF
of 50%–54% (p = 0.0003), and post-anthracycline
LVEF of 50%–54% (p < 0.0001) as significant risk
factors 30. Interestingly, this study also showed a sug-
gestion of increased risk with the use of antihyper-
tensive medications before study entry (p = 0.02) 30.
Of note, left-sided radiation, cardiac arrhythmias, and
other cardiac risk factors were not found to be risk
factors for cardiac toxicity in NSABP B-31 or NCCTG
N98312 30,66. In the HERA trial, a higher cumulative
dose of doxorubicin (287 mg/m2 vs. 257 mg/m2) or
epirubicin (480 mg/m2 vs. 422 mg/m2), a lower
screening LVEF, and a higher body mass index were
all associated with trastuzumab-associated cardiac
dysfunction 67. The other trials have not yet reported
analyses of the predictive factors of trastuzumab-
induced cardiac dysfunction.
3.3.2 Pathogenesis
Little is known about the mechanism of trastuzumab-
induced cardiac dysfunction. The transmembrane
TABLE IV Cardiac toxicity in the trials of adjuvant trastuzumab in early-stage breast cancer
Trial Regimen Patients Follow-up Cardiac Severe Sympto- Decrease Discontinued
(n) (months) death CHF— matic in LVEF trastuzumab
(%) NYHA III/IV CHF, by 15% because of
(%) including or more cardiac
severe from baseline problems
(%) (%) (%)
NSABP B-31 57,64 AC®paclitaxel 814 60 0.1 0.9 [1] NR NA
[36] (n=1)
AC®paclitaxel plus 850 0.0 3.8 [5.1] [14] [19]
trastuzumab for 1 year
NCCTG N9831 57.66 AC®paclitaxel 36 0.1 0.3 NR 6.7 NA
(n=1)
AC®paclitaxel plus 0.0 3.5 17.3 15.4
trastuzumab for 1 year
AC®paclitaxel®trastuzumab 2.5
HERA 58 Chemotherapy®observation 1708 24 0.06 0.00 0.12 2.1 a NA
(n=1)
Chemotherapy® 1678 0.00 0.60 2.15 7.0 a 4.3
trastuzumab for 1 year p=1.0 p<0.0001 p<0.0001 p<0.0001
BCIRG 006 60 AC®docetaxel 1073 36 0.0 0.4 NA 10.1 NA
AC®docetaxel plus 1074 0.0 1.9 18.1 NR
trastuzumab for 1 year
Docetaxel plus carboplatin plus 1075 0.0 0.4 8.6 NR
trastuzumab for 1 year
FinHER 59 Docetaxel®FEC 58 35 0.0 2.8 NA 6.0 NA
Vinorelbine®FEC 58 (n=4) b
Docetaxel plus 54 0.0 0.0 b 3.5 NR
trastuzumab (9 weeks)®FEC
Vinorelbine plus 62 37
trastuzumab (9 weeks)®FEC
a Decrease in left ventricular ejection fraction by 10% or more from baseline and below 50%.
b Includes infarction and cardiac failure.
CHF = congestive heart failure; NYHA = New York Heart Association class; LVEF = left ventricular ejection fraction; NSABP = National Surgical
Adjuvant Breast and Bowel Project; AC = doxorubicin, cyclophosphamide; NR = not reported; NA = not applicable; NCCTG = North Central
Cancer Treatment Group; HERA = Herceptin Adjuvant (Trial); BCIRG = Breast Cancer International Research Group; FinHER = Finland Herceptin
(Trial); FEC = fluorouracil, epirubicin, cyclophosphamide.CARDIAC TOXICITY
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tyrosine kinase receptor HER2 (ErbB2) promotes cell
proliferation when activated 51. To study the role of
ErbB2 signalling in cardiac tissue, mice with a car-
diac-restricted deletion of ERBB2 were bred 68,69. The
mice were viable and displayed no overt deficits at
birth. Over time, the ErbB2-deficient mice were found
to develop features of dilated cardiomyopathy, includ-
ing chamber dilation, wall thinning, and decreased
contractility 68,69. They were also found to be more
susceptible to anthracycline-induced cardiac dysfunc-
tion 68. As a result, the authors suggested that ErbB2
signalling might have a role in myocytes in the pre-
vention of dilated cardiomyopathy triggered by en-
vironmental stressors 68,69.
In contrast to anthracycline cardiac toxicity,
which is irreversible, dose-dependent, and associated
with ultrastructural changes (irreversible myofibril
loss, necrosis, and vacuolar degeneration) 14, trastu-
zumab-associated cardiac toxicity is thought to be
reversible, idiosyncratic, and not associated with
structural damage. In a series investigated by the M.D.
Anderson Cancer Center, 9 of 38 patients with car-
diac toxicity underwent right ventricular endomyo-
cardial biopsies; no ultrastructural changes were
seen 70. This lack of ultrastructural damage may ex-
plain the reversible nature of trastuzumab-related
cardiotoxicity as observed in clinical studies (Perez
EA, Suman VJ, Davidson N, et al. Advances in
monoclonal therapy for breast cancer: further analy-
sis of NCCTG N9831. Presented at the 41st Annual
Meeting of the American Society of Clinical Oncol-
ogy; May 16, 2005; Orlando, FL).
3.3.3 Reversibility of Trastuzumab-Induced Heart
Failure
A retrospective review of 38 patients with trastuzu-
mab-induced cardiotoxicity at M.D. Anderson re-
vealed that the cardiotoxicity might be reversible 70.
Trastuzumab was discontinued in 37 of these patients,
and 31 received standard heart failure treatment,
which included both beta-blockers and angiotensin
converting-enzyme inhibitors 70. All 37 patients
showed improvement in LVEF at 1–3 months. Two
patients had persistent left ventricular dysfunction at
6 months 70. Of the 37 patients, 25 (66%) were
rechallenged with trastuzumab (once stability or im-
provement of left ventricular dysfunction occurred),
and only 3 (12%) developed recurrent left ventricu-
lar dysfunction or symptoms of CHF (or both) prompt-
ing discontinuation of further trastuzumab 70. These
results provided the first suggestion that it may be
safe to reintroduce trastuzumab in patients who de-
velop cardiac dysfunction, once their symptoms or
ejection fraction improve with medical therapy.
In the NSABP B-31 trial, of the 31 patients in the
trastuzumab group who met criteria for symptomatic
CHF 6 months after the onset of heart failure, 26 were
asymptomatic, 1 demonstrated ongoing symptoms of
CHF, and 18 remained on cardiac medications 64. At
6 months after discontinuation of trastuzumab for
either symptomatic CHF or asymptomatic decline in
LVEF, 25% of patients continued to show a LVEF below
50% 30. Data from NCCTG N9831 and BCIRG 006 are
also consistent with this persistent decline in LVEF after
discontinuation of trastuzumab. Of the 14 patients
who had a cardiac event in the NCCTG N9831 trial,
29% continued to show a LVEF below 50% 67. In the
BCIRG 006 trial, 180 of 1040 participants (17.3%)
treated with AC, paclitaxel, and trastuzumab had a
more than 10% reduction in LVEF relative to baseline.
At 42 days, 26% of the participants (37 of 145) had a
persistent decline in LVEF on repeat measurement 61.
These results led to the recognition that, although
most patients recover contractility, a significant pro-
portion of patients (approximately 25% in the trials
already mentioned) experience persistent contractile
dysfunction. Moreover, the long-term implications
of trastuzumab-associated LVEF decline—even in pa-
tients who subsequently recover to baseline LVEF—
are unknown.
3.4 Weighing the Risks and Benefits of Trastuzumab
Ultimately, the risks and benefits of using trastuzu-
mab must be weighed for patients on an individual
basis, taking into account the exclusion criteria used
in the adjuvant trials and the risk factors mentioned
earlier. Many questions remain unanswered: sequen-
tial versus concurrent use of trastuzumab, the neces-
sity of anthracyclines, the long-term significance of
asymptomatic declines in LVEF, and the exact patho-
genesis and risk factors associated with trastuzumab-
induced cardiotoxicity. Also, to date, cardiac toxicity
has been evaluated based on systolic function. Little
is known about possible diastolic dysfunction asso-
ciated with trastuzumab.
The NCCTG N9831 trial found a slightly decreased
incidence of CHF with sequential rather than concur-
rent use of trastuzumab with chemotherapy (2.5%
vs. 3.5%) 62. However, initial reports have suggested
that, as compared with concurrent administration,
sequential administration of trastuzumab may be less
efficacious at preventing breast cancer recurrence
(Perez EA, Suman VJ, Davidson N, et al. Advances
in monoclonal therapy for breast cancer: further
analysis of NCCTG N9831. Presented at the 41st An-
nual Meeting of the American Society of Clinical
Oncology; May 16, 2005; Orlando, FL). Neverthe-
less, the fundamental message of the five trials is
unmistakably clear: trastuzumab, regardless of strat-
egy of administration, clearly has an important role
in reducing the risk of recurrence of HER2-positive
breast cancer. The challenge for the next generation
of clinical studies is therefore to find the means of
delivering trastuzumab in the most efficacious and
least cardiotoxic manner.
Currently, the challenge for clinicians deciding
between sequential and concurrent treatment is toTOWNS et al.
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balance their patients’ cardiac risk with the risk of
tumour recurrence and to discuss this balance with
their patients—especially when the likelihood of ben-
efit may be low for some patients. With this in mind,
the intriguing results of BCIRG 006 raise the question
of whether anthracyclines, with their attendant risk
of cardiac dysfunction, can be omitted in the man-
agement of HER2-positive breast cancer, particularly
for patients at high risk of trastuzumab cardio-
toxicity 61. This question is significant, given that
6.7% of patients who completed doxorubicin and
cyclophosphamide therapy in NSABP B-31 and NCCTG
N9831 were not able to initiate trastuzumab therapy
because of a decline in LVEF after receiving anthra-
cyclines 64. The question of the clinical significance
and long-term outcome of asymptomatic decline in
LVEF also remains. Longer follow-up in all of the ad-
juvant trials is needed to assess the implications of
the asymptomatic LVEF declines seen in NSABP B-31,
NCCTG N9831, HERA, and BCIRG 006. Until then, the
balancing act will continue.
4. AROMATASE INHIBITORS
Aromatase inhibitors are used in postmenopausal
women with hormone receptor–positive breast can-
cer. They act by inhibiting aromatase, the enzyme
responsible for converting androgens to estrogens,
thereby reducing estrogen levels. Unlike tamoxifen,
AIs are not partial estrogen agonists. Tamoxifen acts
as a selective estrogen receptor modulator at the es-
trogen receptor. Because tamoxifen is a partial estro-
gen agonist, it is associated with an increased risk of
thromboembolic events and uterine cancer, and it
protects against bone demineralization. Aromatase
inhibitors are not used alone in premenopausal
women, because they cause a reduction in negative
feedback on the hypothalamic–pituitary axis and
thereby stimulate gonadotropin secretion, which
stimulates the ovaries to produce more androgens,
ultimately increasing estrogen levels 71.
As compared with tamoxifen, third-generation AIs
have been shown to improve DFS in early breast can-
cer. They can be given as first-line hormonal
therapy 72,73, after 2–3 years of treatment with tamox-
ifen (switching to an AI rather than completing 5 years
with tamoxifen) 74–76, or as extended treatment fol-
lowing completion of 5 years of tamoxifen 77. The
switch strategy has also been associated with an over-
all survival benefit in HER2-positive patients 75.
4.1 AIs and Cardiac Toxicity
4.1.1 First-line Hormonal Therapy Trials
The Breast International Group (BIG) 1-98 trial is a
four-arm trial of letrozole as compared with tamoxi-
fen for 5 years. The two additional arms were estab-
lished to evaluate the early-switch strategy to
tamoxifen from letrozole or to letrozole from tamox-
ifen. So far, only the results of upfront letrozole alone
as compared with tamoxifen alone have been reported.
Patients on letrozole experienced improved DFS,
but overall survival did not differ significantly between
groups (Table V) 74,76–80. The rate of all adverse car-
diac events was 4.8% in the letrozole group and 4.7%
in the tamoxifen group (p = 0.87) 78. Concerns arose
when it was noted that, as compared with women in
the tamoxifen arm, women in the letrozole arm had
significantly more grades 3, 4, and 5 cardiac events
(based on the Common Toxicity Criteria, version 2,
of the U.S. National Cancer Institute: 2.4% vs. 1.21%,
p = 0.001) 78. These data must be interpreted with cau-
tion because baseline cardiovascular disease, LVEF, and
cardiac risk factors were not reported. The letrozole
group also experienced a lesser improvement in cho-
lesterol profile than did the tamoxifen group 78. The
Arimidex, Tamoxifen Alone or in Combination trial
also found a statistically significant improvement in
DFS with anastrozole (Arimidex: AstraZeneca Phar-
maceuticals, Wilmington, DE, U.S.A.) as compared
with tamoxifen 79. That study detected no significant
difference in the rates of ischemic cardiovascular dis-
ease between groups 79.
4.1.2 Switching to an AI After 2–3 Years of Tamoxifen
Versus 5 Years of Tamoxifen
The Intergroup Exemestane Study (IES), a combined
analysis of the Austrian Breast and Colorectal Can-
cer Study Group (ABCSG) 8 study and the Arimidex–
Nolvadex (ARNO)–95 trial, and the Italian Tamoxifen
Anastrozole (ITA) trial all compared tamoxifen alone
for 5 years with 2–3 years of tamoxifen followed by
an AI to reach a full 5 years of hormonal therapy. The
switch to an AI was associated with a significantly
longer DFS in all of those trials 74,76,80. In the IES trial,
a trend towards increased cardiac events with
exemestane as compared with tamoxifen was noted 80.
None of the trials found a statistically significant dif-
ference in cardiac events between the AI and tamoxi-
fen groups 74,76. In the ITA trial, a greater rate of lipid
metabolism disorders (not defined in the publication
from that study) was seen in the anastrozole arm
(8.1% vs. 1.4% in the tamoxifen group, p = 0.01).
No comparison to baseline lipid profiles was reported.
Notably, the IES trial and the combined analysis of
ABCSG-8 and ARNO-95 excluded patients with a “clini-
cally significant cardiac disorder” or “uncompensated
cardiac insufficiency” 74,75. However, without clear
reporting of baseline cardiovascular risk factors, it is
difficult to know how to apply the results of these
safety analyses to patients with an elevated risk of
cardiovascular disease.
4.1.3 Extended Treatment with AIs After Completion of
5 Years of Tamoxifen
The MA.17 trial reported no significant difference in
its AI and placebo arms with regard to the rate of car-
diovascular events after 5 years of tamoxifen 77. TheCARDIAC TOXICITY
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rates of hypercholesterolemia were 11.9% in the
letrozole group and 11.5% in the placebo group (p =
0.67) 77. This trial reported previous diagnoses of
cardiovascular disease at baseline, and rates of car-
diovascular disease were comparable in both groups
(letrozole: 12%; placebo: 11%). Notably, the MA.17
trial is the only trial that compared an AI to placebo
rather than to tamoxifen, providing a clearer assess-
ment of the cardiac safety of AIs. However, given that
all of the patients had previously been treated with
tamoxifen for 5 years, it is difficult to determine the
protective effect that that treatment may or may not
have had, and how to interpret the data for patients
who will be treated with 5 years of AI therapy up front,
without tamoxifen.
4.2 Are AIs Cardiotoxic?
Based on the foregoing data, AIs appear to be associ-
ated with a slightly greater incidence of cardiovascu-
lar endpoints; however, such comparisons are not
statistically significant in most of the adjuvant AI tri-
als. Nevertheless, it must be remembered that these
trials were not designed to address the issue of car-
diac disease. By in large, they did not clearly define
criteria for cardiac endpoints or prospective evalua-
tion of cardiac safety 81. In addition, clinical follow-
up from these trials is currently short, and longer
follow-up is required to determine the true cardiac
safety of AIs in the long term.
5. SUMMARY
The advances made in adjuvant systemic therapy have
been very successful in reducing the mortality rate
associated with breast cancer. More women are now
living with breast cancer and more patients are also
now receiving a combination of therapies: chemo-
therapy, targeted therapy, and endocrine treatments.
Therefore, addressing the long-term toxicity of treat-
ments is critical.
The present article has highlighted cardiac toxic-
ity as one of the key long-term toxicities of adjuvant
systemic therapy. It is important for all practitioners
to recognize this toxicity and to make an attempt to
reduce its onset by selecting appropriate patients for
adjuvant therapy, by selecting appropriate therapy
based on patient factors and risk of recurrence, and
by increasing awareness and education in patients and
allied health care staff about cardiac toxicity. Al-
though optimizing adjuvant therapy to reduce the risk
of breast cancer recurrence is critical, recognizing and
managing related toxicity is also important.
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